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1. Need for digital health during the COVID-19 pandemic 
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2), started in the city of Wuhan late in 2019. Within a few months, the disease spread toward 
all parts of the world and was declared a pandemic on March 11, 2020. The current health care dilemma 
worldwide is how to sustain the capacity for quality services not only for those suffering from COVID-19 
but also for non-COVID-19 patients, all while protecting physicians, nurses, and other allied health care 
workers.  
The pandemic poses challenges to electrophysiologists at several levels. Hospitalized COVID-19-positive 
patients may have preexisting arrhythmias, develop new arrhythmias, or be placed at increased 
arrhythmic risk from therapies for COVID-19. Cardiac arrhythmia incidence in hospitalized patients has 
been documented in a few published studies, with reported rates of 7.9%1 and 16.7%2 in hospitals in 
New York City and Wuhan, respectively, and up to 44%2 in patients requiring intensive care. Life-
threatening arrhythmias (ventricular tachycardia [VT]/ventricular fibrillation [VF]) can occur in up to 6% 
of hospitalized patients with COVID-19 infection.3 There have also been several case reports of 
atrioventricular block in hospitalized patients, which is otherwise rarely described during viral illness.4,5 
Although the residual left ventricular dysfunction and arrhythmic risk are currently unknown, 
preliminary pathophysiological,6 histological,7 and imaging8 data suggest that SARS-CoV-2 infection holds 
the potential to induce durable myocardial changes predisposing to arrhythmias or heart failure. 
Electrocardiographic monitoring and inpatient monitoring services may become necessary but face the 
potential hurdles of limited telemetry wards, contamination of equipment and infection of health care 
personnel, and shortage of personal protective equipment.9,10 In parallel, there is a continued 
responsibility to maintain care of COVID-19-negative patients with arrhythmias. These pressures have 
led to inventive utilization and adaptation of existing telemedicine technologies as alternative options. 
This document discusses how digital health may facilitate electrophysiology practice for patients with 
arrhythmia, whether hospitalized for COVID-19 or not. The representation of authors from some of the 
most severely affected countries, such as China, Spain, Italy, and the United States, is a tribute from our 
worldwide community to those colleagues who have worked on the front lines of the pandemic.  
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2.  Monitoring strategies during a pandemic: Here to stay 
In light of the current pandemic, monitoring strategies should focus on selecting high-risk patients in 
need of close surveillance and using alternative remote recording devices to preserve personal 
protective equipment and protect health care workers from potential contagious harm. 
Inpatient 
For inpatient monitoring, telemetry is reasonable when there is concern for clinical deterioration (as 
may be indicated by acute illness, vital signs, or sinus tachycardia), or in patients with cardiovascular risk 
factors and/or receiving essential QT-prolonging medications. Telemetry is generally not necessary for 
persons under investigation without concern for arrhythmias or clinical deterioration and in those not 
receiving QT-prolonging drug therapy. In situations in which a hospital’s existing telemetry capacity has 
been exceeded by patient numbers or when conventional telemetry monitoring is not feasible, such as off-
site or nontraditional hospital units, mobile devices may be used, for example, mobile cardiac outpatient 
telemetry (MCT) as an adjunctive approach to support inpatient care.11-15 The majority of MCT devices can 
provide continuous arrhythmia monitoring using a single-lead electrocardiogram (ECG) and allow for real-
time and offline analysis of long-term ECG data. Telemetry can be extended using patch monitoring.16,17 
Smartphone ECG monitors are wireless and have also been utilized during the current pandemic. 
Information is limited, however, on how parameters such as QTc measured on a single- (or limited 
number) lead ECG can reliably substitute for 12-lead ECG information.18,19 In one study, QT was 
underestimated by smartphone single-lead ECG.20 
Outpatient  
The principles of remote patient management, crossing geographic, social, and cultural barriers, can be 
extended to outpatient care and are important to maintain continuity of care for non-COVID-19 
patients.21-23 Virtual clinics move far beyond simple telephone contacts by integrating information from 
photos, video, mobile heart rhythm and mobile health devices recording ECG, and remote 
cardiovascular implantable electronic device (CIED) interrogations.24 A variety of platforms have been 
developed and used specifically to provide telehealth to patients via video teleconferencing25,26 (Table 
1). Most health care centers have expanded use of telemedicine, with some reporting 100% 
transformation of in-person clinic visits to telemedicine-based visits in order to maintain care for non-
COVID-19 patients, thus obviating their need to come to the hospital or clinic. This supplements social 
distancing measures and reduces the risk of transmission, especially for the older and more vulnerable 
populations. It also becomes a measure to control intake into emergency rooms and outpatient facilities 
and to permit rapid access when necessary to subspecialists. 
Electrophysiology is well placed for virtual consultations. All preobtained data, including ECGs, 
ambulatory ECG monitoring, cardiac imaging, and coronary angiography can be adequately reviewed 
electronically. Digital tools such as direct-to-consumer mobile ECG (Table 2) and wireless blood pressure 
devices can be used to further complement the telehealth visit without in-person contact. CIED, 
wearable/mobile health, and clinical data can be integrated into clinician workflow.  
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Table 1  Examples of commonly used platforms for telehealth
25-27 
 Platform  Website 
HIPAA- or PHI-secure 
telehealth platform 
accuRx
*
 https://www.accurx.com  
AMD Global Telemedicine
†
 
https://www.amdtelemedicine.com/telemedicine-
products/Working-Clinic-Telemedicine.html  
American Well
‡
 https://business.amwell.com/solution-overview 
Attend Anywhere
*
 https://www.attendanywhere.com  
BlueJeans for Healthcare
‡
 https://www.bluejeans.com/use-cases/healthcare 
Care Connect by KRY/LIVI
§
 https://www.kry.care  
Caregility
‡
 https://caregility.com/uhe-applications  
Cisco Webex
†
 https://www.webex.com/webexremotehealth.html  
ClickDoc
§
 https://www.cgm.com/be/index.fr.jsp  
Conexa Saúde
¶
  https://www.conexasaude.com.br 
Docobo* https://www.docobo.co.uk  
Doctena
§
 https://secure.doctena.com 
Doctorlink
*
  https://www.doctorlink.com/video-consultation 
Doximity
‡
  https://www.doximity.com 
Doxy.me
‡
 https://doxy.me 
EMIS Health Video Consult
*
 
https://www.emishealth.com/products/video-
consultation 
Exprivia
§
 https://www.exprivia.it  
FaceTalk
§
 https://facetalk.nl  
Google G Suite
†
  https://gsuite.google.com/industries/healthcare  
Helena
§
 https://qa.helena.care  
Intersysto
§
 http://www.intersysto.eu 
InTouch Health
‡
 https://intouchhealth.com/telehealth-solutions  
pMD
‡
  https://www.pmd.com/secure-messaging-telemedicine  
Microsoft Teams/Skype for Business E3 
and E5
†
  
https://www.microsoft.com/en-us/microsoft-
365/microsoft-teams/healthcare-solutions 
Signal
§,Δ
 https://signal.org  
Silicon Practice FootFall
*
  https://www.siliconpractice.co.uk/video-consultations  
Spruce
‡
 https://www.sprucehealth.com 
TeleMedi
§
 https://telemedi.be  
Updox
‡
 https://www.updox.com  
US Department of Veterans Affairs Video 
Connect
‡ 
 
https://www.mobile.va.gov/app/va-video-connect 
VSee
‡
  https://vsee.com 
Zoom for Healthcare
†
 https://zoom.us/healthcare  
Proprietary EMR telehealth platforms      
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Video-conferencing 
platforms (not HIPAA- 
or PHI-secure) 
GoToMeeting  
Skype  
Zoom   
Non-public-facing 
mobile 
communication 
platforms (not HIPAA- 
or PHI-secure) 
Apple FaceTime   
Google Duo   
Google Hangouts   
WhatsApp   
*United Kingdom. †Global. ‡United States. §Europe. ¶South America—Brazil. ∆Encrypted, but not specifically a telehealth 
platform. EMR = electronic medical record; HIPAA = Health Insurance Portability and Accountability Act; PHI = protected health 
information. 
  
Table 2    Examples of remote ECG and heart rate monitoring devices  
  Device Type CE mark 
FDA 
clearance 
Additional 
features/Notes 
Website 
Handheld 
devices 
AliveCor 
KardiaMobile  
Wireless Yes Yes 
FDA cleared for 
AF (1-lead) and 
for QTc (6L) for 
COVID-19 
patients on 
HCQ±AZM 
https://www.alivecor.com/ka
rdiamobile  
Beurer ME 90 
Wireless 
1-lead ECG 
Yes No   
https://www.beurer.com/we
b/gb/products/medical/ecg-
and-pulse-oximeter/mobile-
ecg-device/me-90-
bluetooth.php  
Cardiac Designs 
ECG Check 
Wireless 
1-lead ECG  
Yes Yes   https://www.cardiacdesigns.com  
CardioComm 
Solutions 
HeartCheck 
CardiBeat and ECG 
Pen 
Wireless 
1-lead ECG 
Yes Yes   https://www.theheartcheck.com  
COALA 
Wireless 
1-lead ECG 
Yes Yes 
Remote lung 
auscultation 
https://www.coalalife.com  
Eko DUO 
Wireless 
1-lead ECG 
Yes Yes  
Remote cardiac 
auscultation/ 
phonocardiogram 
https://www.ekohealth.com  
Omron Blood 
Pressure + EKG 
Monitor 
Wireless 
1-lead 
ECG+BP cuff 
No Yes 
United States and 
Canada only  
https://omronhealthcare.com  
EKGraph 
Wireless 
1-lead ECG 
 No Yes United States https://sonohealth.org  
Mobile cardiac 
telemetry 
devices 
Qardio  
QardioCore 
Chest strap 
1-lead ECG 
Yes No 
ECG, HR, HRV, 
RR, activity 
https://www.getqardio.com/
qardiocore-wearable-ecg-ekg-
monitor-iphone  
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  Device Type CE mark 
FDA 
clearance 
Additional 
features/Notes 
Website 
BardyDx CAM 
Patch 
1-lead ECG 
Yes Yes 
Under clinical 
investigation for 
QTc monitoring 
in COVID-19 
patients 
https://www.bardydx.com  
BioTel Heart 
Patch 
1-lead ECG 
Yes—only 
for 
extended 
Holter 
Yes 
FDA cleared for 
QTc monitoring 
https://www.myheartmonitor
.com/device/mcot-patch  
iRhythm Zio 
patch/Zio AT 
Patch 
1-lead ECG 
Yes Yes   https://www.irhythmtech.com  
InfoBionic MoMe 
Kardia 
Wired 
3-lead ECG  
Yes Yes 
Remote lung 
auscultation 
https://infobionic.com  
MediBioSense 
MBS HealthStream, 
VitalPatch, MCT  
Patch 
1-lead ECG 
Yes Yes 
Monitors up to 8 
vital signs 
https://www.medibiosense.com  
MEMO Patch 
Patch/watch 
1-lead ECG 
No No 
Asia; Korea FDA 
approved 
https://www.huinno.com     
Medilynx 
PocketECG 
Wired 
3-lead ECG 
Yes Yes HRV https://www.pocketecg.com  
RhythMedix 
RhythmStar 
Wired 
3-lead ECG 
No Yes   https://www.rhythmedix.com  
Samsung S-patch 
Cardio 
Patch 
1-lead ECG 
Yes No 
Asia; Korea FDA 
approved 
https://www.samsungsds.co
m/global/en/solutions/off/car
dio/cardio.html  
Smartwatches 
Apple Watch 1-lead ECG Yes Yes 
FDA cleared for 
AF notification 
https://www.apple.com/watch  
Withings Move ECG 1-lead ECG Yes No 
Requires Health 
Mate app for ECG 
analysis/AF 
detection 
https://www.withings.com/us
/en/move-ecg  
AF = atrial fibrillation; AZM = azithromycin; BP = blood pressure; ECG = electrocardiogram; FDA = Food & Drug 
Administration; HCQ = hydroxychloroquine; HR = heart rate; HRV = heart rate variability; RR = respiratory rate. 
Additional diagnostic information might be obtained without in-person contact using home enrollment 
of prescribed ambulatory rhythm monitors. Patch monitors can be mailed to patient homes and easily 
self-affixed, unlike Holter monitors with cables and electrodes requiring placement by health care 
workers. In some cases, new or follow-up telehealth visits will require an adjunctive in-person visit to 
perform a 12-lead ECG, ECG stress test, echocardiogram, or other diagnostic procedures. Occasionally, 
conventional clinic visits are required to accurately assess the impact of comorbidities or frailty on 
procedural risk, or to allow comfortable discussion with multiple family members when planning 
procedures with high risk. Telephone-only visits (ie, without video) may allow for a broader reach due to 
ease and ubiquitous accessibility as a communication strategy for immediate access for urgent matters.  
There are many barriers to implementation, such as inadequate reimbursement, licensing/regulatory 
and privacy issues, lack of infrastructure, resistance to change, lack of access/poor Internet coverage, 
restricted financial resources, and limited technical skills (eg, in the elderly patient population). Some 
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telehealth and remote ECG monitoring technologies may be simply unaffordable and/or unavailable, 
leading to different levels of uptake within communities and across the globe. All stakeholders should 
collaborate to address these challenges and promote the safe and effective use of digital health during 
the current pandemic. In recent months, regulations have been eased to permit consults with new 
patients, issuing prescriptions, and obtaining consents. In that sense, the COVID-19 pandemic may serve 
as an opportunity to evolve current technologies into indispensable tools for our future cardiological 
practice. 
3. Therapy for COVID-19 and potential electrical effects 
No specific cure exists for COVID-19.28-30 Potential COVID-19 therapies, especially hydroxychloroquine 
and azithromycin, are being investigated in ongoing trials but also have been used off label in many 
parts of the world. These may exert QT-prolonging effects31 (Table 3) and, since recent observational 
data have questioned their efficacy, require a careful risk-benefit adjudication.32 Combination therapy 
(eg, hydroxychloroquine and azithromycin) may have synergistic effects on QT prolongation.33,34 In a 
retrospective cohort study of 1,438 COVID-19 patients hospitalized in metropolitan New York (ie, a 
disease epicenter), cardiac arrest was more frequent in patients who received hydroxychloroquine with 
azithromycin compared with patients who received neither drug.35 The adjusted hazard ratio for in-
hospital mortality for treatment with hydroxychloroquine alone was 1.08, for azithromycin alone was 
0.56, and for combined hydroxychloroquine and azithromycin was 1.35. However, none of these hazard 
ratios were statistically significant. The observational design of this study may limit interpretation of 
these findings. In the absence of clear efficacy data, treatment options should be individualized taking 
into account their proarrhythmic potential for torsade de pointes, which may be enhanced by 
concomitant administration of other QT-prolonging drugs (eg, antiarrhythmics, psychotropics, etc). 
Table 3  Effect on QTc and proarrhythmia of experimental pharmacological therapies for COVID-19
36  
 QTc prolongation TdP risk 
Chloroquine
37-40
 Moderate ↑ Low risk of TdP 
Hydroxychloroquine
41
 Moderate ↑ Low risk of TdP 
Azithromycin
42-48
 Moderate ↑ Very low risk of TdP 
Lopinavir/ritonavir
37
 Moderate ↑ Low risk of TdP 
Tocilizumab
49
 Mild ↑ or ↓ NR 
Fingolimod Mild ↑ NR 
Remdesivir NR NR 
Interferon alfacon-1 NR NR 
Ribavirin NR NR 
Methylprednisolone NR NR 
NR = not reported; TdP = torsade de pointes. 
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In COVID-19 patients receiving prior antiarrhythmic therapy, there should be a thorough consideration 
of risk vs benefit before initiating any QT-prolonging COVID-19 therapies, especially considering their 
unproven value. For instance, although some recent observational studies highlight adverse effects of 
hydroxychloroquine in treating this infectious disease, its use is likely to persist outside of randomized 
trials because of its affordability and global availability compared with, for example, remdesivir.35 If one 
of these drugs is judged to be critical, monitoring should be initiated. If life-threatening arrhythmias 
(VT/VF) occur, the benefit of antiarrhythmic drugs, notably amiodarone, outweighs the potential harm 
of hydroxychloroquine or other QT-prolonging drugs targeting COVID-19, and in these cases 
antiarrhythmic drugs should be prioritized and used as deemed necessary. Most importantly, all 
modifiable predisposing factors for QTc prolongation (electrolyte disturbances, drug-to-drug interaction) 
that may enhance arrhythmia susceptibility should be corrected, and the small subset of individuals with 
an underlying genetic predisposition such as congenital long QT syndrome (in whom QTc-prolonging 
medications are contraindicated) should be identified. Additionally, caution must be exercised in case of 
subclinical or manifest myocarditis that may increase the vulnerability to proarrhythmias associated 
with QT-prolonging drugs.  
If drugs that exert a QT-prolonging effect are to be initiated in an inpatient setting, a baseline 12-lead 
ECG should be acquired. Following review of the QTc, patients can be stratified into low-risk group (QTc 
of <500 ms or <550 ms in the setting of wide baseline QRS) or high-risk group (baseline QTc of ≥500 ms 
or ≥550 ms in the setting of wide baseline QRS, or patients who are started on combination therapies), 
guiding selection of telemetered vs nonmonitored beds.50 Low-risk patients treated with QT-prolonging 
agents may be monitored using MCT (or another available wearable) with twice-a-day transmission of 
QTc measurements and any urgent alerts. High-risk patients would require more continuous monitoring 
and follow-up QTc measurements using telemetry preferably (but if unavailable, other remote 
monitoring devices). A second QTc assessment via telemetry or other remote devices after 2 doses may 
be helpful in identifying “QTc reactors”—patients who have an exaggerated response to QT-prolonging 
agents. An increase in QTc by ≥60 ms or to QTc ≥500 ms on any follow-up QT assessment is considered 
significant and should prompt a reassessment of risks vs benefits of continuing the drug.  
In the outpatient setting, a recent statement from the US Food & Drug Administration (FDA) “cautions 
against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a 
clinical trial due to risk of heart rhythm problems.” (This does not affect FDA-approved uses for malaria, 
lupus, and rheumatoid arthritis.)51 Exceptions to this practice are acknowledged to occur in some 
regions, as these drugs have been used outside the United States without regulatory warnings. Under 
these conditions, or when these drugs are maintained after hospital discharge, consumer mobile ECG 
devices capable of generating QTc measurements may be used. If the QTc increases significantly, 
physicians can consider a change or discontinuation of medication via the phone or virtual medical 
services.  
Electrocardiographic monitoring during clinical trials 
Several double- and multi-arm blind randomized controlled trials are underway worldwide for COVID-19 
outpatients utilizing different medications that may prolong the QT interval.52-56 These drugs are being 
tested either alone or in various combinations and are being compared with one another, with 
differential dosing regimens and/or placebo. These drugs are also being tested for postexposure 
prophylaxis in high-risk groups.  
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Mobile health using smartphone-based portable ECG devices as QTc monitoring tools is an innovative 
and economical solution to conduct monitoring in outpatient trials. For instance, in one trial evaluating 
hydroxychloroquine and azithromycin (hydroxychloroquine alone and hydroxychloroquine/azithromycin 
combination) against a placebo, participants receive remote training to acquire a 6-lead ECG at baseline 
and then at specified follow-up intervals through the trial period (Figure 1). These ECGs are transmitted 
to a remote QTc monitoring site, where the QTc is assessed and monitored over the treatment period.  
 
 
Figure 1     Electrocardiogram (ECG) acquisition and transmission using a smartphone-based portable ECG monitor. 
 
4. The future: Digital medicine catalyzed by the pandemic  
The COVID-19 public health emergency has forced changes to traditional norms of health care access 
and delivery across all continents.10 It has accelerated adoption of telemedicine and all aspects of digital 
health, regarded as a positive development. Today’s new reality will likely define medicine going 
forward. Many monitoring and diagnostic testing aspects of both inpatient and outpatient care will be 
increasingly served by digital medicine tools. 
The need for contactless monitoring for inpatients triaged to intensive care unit, telemetry, or 
nonconventional environments, as well as for outpatients needing continued management, has 
triggered novel implementation of digital health monitoring tools. Some centers have created 
algorithms based on predictive analytics of electronic medical record (EMR) data. Centralized monitoring 
or mobile continuous monitoring has improved patient outcomes, reduced manpower needs, and is 
being utilized more commonly.57 The use of wearables such as watches, smartphones, and smart beds 
(with elimination of cables and skin electrodes) for in-hospital telemetry is a novel approach. This type 
of wireless monitoring may be continued after discharge, permitting prolonged surveillance of rhythm 
and other physiological parameters.12 Bracelet technologies may transmit multiple parameters (eg, 
heart rate, sleep, oxygen desaturation index, blood pressure) via a smartphone link to centralized hubs. 
These technologies provide a solution for intensive monitoring extending beyond the hospital 
environment.  
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Outpatient management has been revolutionized since the start of the pandemic. Social distancing 
measures and restricted clinic access have driven the rapid adoption of telehealth mechanisms to 
continue management of non-COVID-19 patients. Virtual visits that have been used for decades to reach 
isolated communities,58 but less commonly utilized in advanced health systems, have now become the 
mainstay of ambulatory care across all subspecialties. The initial experience appears to have been 
positive for both patient and caregiver. Heart rhythm professionals are fortunate to have a choice of 
wireless technologies to relay monitored information to maintain connection.12 Wearable and 
smartphone-based devices allow convenient real-time monitoring for arrhythmias on a long-term basis 
due to the comfort associated with their small size and ease of use while reducing patient and health 
care worker exposure. Remote CIED monitoring has existed for decades.24 It is strongly endorsed by 
professional societies, but in practice only a fraction of its diagnostic and therapeutic capabilities has 
been utilized—until now.59 Since the start of the pandemic, utilization of wireless communication with 
CIEDs has grown exponentially, permanently altering the future of device follow-up. Patient outcomes 
may be improved with intensive device-based monitoring compared with traditional in-clinic evaluations 
at regular intervals.60 Recent data indicate that in-person CIED evaluation can be extended safely to at 
least biennially when daily digital connectivity is maintained.61 Remote monitoring has the potential 
advantage of detecting and alerting caregivers (and in the future—patients directly) about important 
parameter changes, enabling earlier patient hospitalization, even during a presymptomatic phase.62 
Connectivity permits longitudinal follow-up, with advantages ranging from individual disease 
management to assessment of penetration of recommended therapies into communities.60,63 The ability 
for CIED remote monitoring data to be streamed to or accessed by multiple providers can facilitate 
communication and cooperative treatment and should be encouraged. This will require approval by 
patients, regulators, and manufacturers. Lessons learned from implantable devices can be applied 
widely in telemedicine. Regulatory bodies have been responsive, for example, approving smartphone-
based QT interval measurement and telehealth services across state lines in the United States. The 
pandemic experience should serve as an impetus to expedite the resolution of persistent challenges, 
such as validation of digital technologies, infrastructure for data management (and mechanism for relay 
to patient and caregiver), interoperability with EMR, application of predictive analytics, cybersecurity 
(and with it the capability for limited forms of remote CIED programming), and reimbursement.64-66  
In summary, the crisis precipitated by the pandemic has catalyzed the adoption of remote patient 
management across many specialties and for heart rhythm professionals, in particular. This practice is 
here to stay—it will persist even if other less arrhythmogenic treatment strategies evolve for COVID-19 
and after the pandemic has passed. This is an opportunity to embed and grow remote services in 
everyday medical practice worldwide. 
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